These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31888982)

  • 1. QnAs with H. Michael Shepard and Dennis J. Slamon.
    Davis TH
    Proc Natl Acad Sci U S A; 2020 Jan; 117(2):796-798. PubMed ID: 31888982
    [No Abstract]   [Full Text] [Related]  

  • 2. H. Michael Shepard, Dennis J. Slamon, and Axel Ullrich honored with the 2019 Lasker~DeBakey Clinical Medical Research Award.
    Williams CL
    J Clin Invest; 2019 Oct; 129(10):3963-3965. PubMed ID: 31499488
    [No Abstract]   [Full Text] [Related]  

  • 3. Herceptin: A First Assault on Oncogenes that Launched a Revolution.
    Sawyers CL
    Cell; 2019 Sep; 179(1):8-12. PubMed ID: 31519311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER-2/neu testing comes of age.
    Wisecarver JL
    Am J Clin Pathol; 1999 Mar; 111(3):299-301. PubMed ID: 10078102
    [No Abstract]   [Full Text] [Related]  

  • 5. Recent Developments and Future Directions with HER-2 in Breast Cancer and Other Tumor Types. Proceedings of a roundtable. August 11-14, 1999. Olympic Valley, California, USA.
    Semin Oncol; 2000 Dec; 27(6 Suppl 11):1-100, quiz 101-10. PubMed ID: 11245159
    [No Abstract]   [Full Text] [Related]  

  • 6. [Herceptin].
    Morginstin T; Shani S; Shemer J
    Harefuah; 2000 Mar; 138(6):459-64. PubMed ID: 10883160
    [No Abstract]   [Full Text] [Related]  

  • 7. Should we treat HER, too?
    Hayes DF
    J Clin Oncol; 1996 Mar; 14(3):697-9. PubMed ID: 8622013
    [No Abstract]   [Full Text] [Related]  

  • 8. Proceedings of the HER2 State of the Art Conference. 21-23 November 1999. Montreux, Switzerland.
    Ann Oncol; 2001; 12 Suppl 1():1-107. PubMed ID: 11816498
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeting HER2 in prostate cancer: where to next?
    Solit DB; Rosen N
    J Clin Oncol; 2007 Jan; 25(3):241-3. PubMed ID: 17235040
    [No Abstract]   [Full Text] [Related]  

  • 10. What is the ideal HER2 test for Herceptin therapy?
    Jpn J Clin Oncol; 2000 Apr; 30(4):208-9, 211. PubMed ID: 10830993
    [No Abstract]   [Full Text] [Related]  

  • 11. Focus on ERBB2.
    Benusiglio PR
    Pharmacogenomics; 2008 Jul; 9(7):825-8. PubMed ID: 18597646
    [No Abstract]   [Full Text] [Related]  

  • 12. Predicting response to herceptin therapy.
    Lipton A; Leitzel K; Ali S
    Clin Cancer Res; 2004 Mar; 10(5):1559-60. PubMed ID: 15014003
    [No Abstract]   [Full Text] [Related]  

  • 13. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
    Paik S; Kim C; Wolmark N
    N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751
    [No Abstract]   [Full Text] [Related]  

  • 14. The distinctive nature of HER2-positive breast cancers.
    Burstein HJ
    N Engl J Med; 2005 Oct; 353(16):1652-4. PubMed ID: 16236735
    [No Abstract]   [Full Text] [Related]  

  • 15. Trastuzumab in the treatment of breast cancer.
    Hortobagyi GN
    N Engl J Med; 2005 Oct; 353(16):1734-6. PubMed ID: 16236745
    [No Abstract]   [Full Text] [Related]  

  • 16. Optimising the Role of Herceptin in Breast Cancer. Symposium proceedings. Monte Carlo, June 19-21, 2000.
    Oncology; 2001; 61 Suppl 2():1-91. PubMed ID: 11758500
    [No Abstract]   [Full Text] [Related]  

  • 17. HER-2 and fluorescent in situ hybridization to evaluate breast cancer.
    Tanvetyanon T
    JAMA; 2004 Jul; 292(3):328; author reply 328-9. PubMed ID: 15265845
    [No Abstract]   [Full Text] [Related]  

  • 18. New molecule-targeting therapy with herceptin (trastuzumab), an anti-HER2 (c-erB-2) monoclonal antibody.
    Sakamoto G; Mitsuyama S
    Breast Cancer; 2000; 7(4):350-7. PubMed ID: 11114864
    [No Abstract]   [Full Text] [Related]  

  • 19. HER2/neu in the management of invasive breast cancer.
    Meric F; Hung MC; Hortobagyi GN; Hunt KK
    J Am Coll Surg; 2002 Apr; 194(4):488-501. PubMed ID: 11949754
    [No Abstract]   [Full Text] [Related]  

  • 20. Will single-time tumor profiling and a "guilt by association" approach allow us to outsmart HER2-positive breast cancer?
    Arteaga CL
    Clin Cancer Res; 2007 Feb; 13(4):1071-3. PubMed ID: 17317812
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.